Elevra Lithium Q4 revenue falls 61% QoQ, but FY26 total rises 37% to US$198M
Elevra Lithium's Q4 FY26 revenue fell 61% QoQ to US$31 million as a legacy contract ended, causing a price drop. However, full-year FY26 revenue grew 37% YoY to US$198 million, supported by strong production gains.

*this image is generated using AI for illustrative purposes only.
Elevra Lithium Limited (ASX: ELV, NASDAQ: ELVR) reported a 61% quarter-on-quarter revenue decline to US$31 million for the June 2026 quarter, driven by a 39% drop in tonnes sold and a 37% decrease in average realised selling prices. Despite this quarterly contraction, the company’s full-year FY26 revenue rose 37% year-on-year to US$198 million. The Q4 revenue dip reflects the finalisation of a multi-year contractual agreement that included a lagged pricing mechanism, which did not capture recent lithium price increases. With this legacy contract now complete, management expects future pricing in Q1 FY27 and beyond to align more closely with spot market rates.
Operational performance at the North American Lithium (NAL) mine improved significantly, with spodumene concentrate production increasing 15% quarter-on-quarter to 54,479 dry metric tonnes (dmt). This output represented the second-best quarterly performance on record, supported by high mill utilisation of 92% and improved lithium recoveries of 71%, a 5% increase from the prior quarter. Ore mined remained stable at 372,938 wet metric tonnes (wmt), aligning with process plant requirements. Safety performance remained robust, with no lost-time injuries recorded during the period.
Unit operating costs per tonne sold (FOB) increased 3% to US$907/dmt, primarily due to the release of higher-cost inventory following a planned major plant shutdown in April 2026. Capital expenditure for the quarter was US$4 million, allocated to sustaining capital projects and the NAL Expansion Scoping Study. The company ended the quarter with a cash balance of US$255 million, resulting in net cash of US$200 million after accounting for a US$55 million prepayment facility.
Strategic Financing and Portfolio Adjustments
Elevra secured a Strategic Financing Package comprising a US$196 million institutional placement and US$102 million in Convertible Notes issued to the Canada Growth Fund (CGF). Shareholders approved the upfront tranche of US$46 million (C$65 million) at an Extraordinary General Meeting on 16 July 2026. This funding fully supports the NAL Brownfield Expansion, which an updated scoping study indicates will accelerate production growth by two years and more than double the incremental post-tax net present value to C$969 million. Additionally, Elevra agreed to sell its interest in the Ewoyaa Project in Ghana to Zhejiang Huayou Cobalt Co., Ltd. for approximately US$71 million in cash, simplifying its corporate structure and focusing capital on North American assets.
Operational Financial Performance
| Metric | Unit | Q4 FY26 | Q3 FY26 | QoQ Variance |
|---|---|---|---|---|
| Ore mined | wmt | 372,938 | 370,508 | 1% |
| Concentrate produced | dmt | 54,479 | 47,332 | 15% |
| Concentrate sold | dmt | 33,977 | 55,526 | (39%) |
| Avg realised price (FOB) | US$/dmt | 921 | 1,453 | (37%) |
| Revenue | US$M | 31 | 81 | (61%) |
| Unit operating cost (FOB) | US$/dmt | 907 | 884 | 3% |
| Cash balance | US$M | 255 | 113 | 126% |
What the Numbers Show
The divergence between rising production and falling Q4 revenue highlights the transitional nature of Elevra’s current commercial cycle. While physical output increased by 15% to 54,479 dmt, sales volumes dropped by 39% to 33,977 dmt, indicating a buildup of inventory rather than a demand shortfall. The 37% decline in average realised price was entirely attributable to the lagged pricing mechanism of the expiring legacy contract, not a drop in spot market values. However, the 37% year-on-year increase in full-year FY26 revenue to US$198 million demonstrates that strong performance in earlier quarters offset the Q4 drag. As the legacy contract concludes, the alignment between the company’s improved operational efficiency—evidenced by the 5% jump in recovery rates—and spot-market pricing should materially improve future margins. The substantial cash position of US$255 million provides ample liquidity to execute the funded NAL expansion without near-term financing pressure.
How will the transition from legacy lagged pricing to spot-market rates in Q1 FY27 impact Elevra's gross margins given the current US$907/dmt operating cost?
What is the projected timeline for the NAL Brownfield Expansion to reach full production capacity, and how will the accelerated two-year schedule affect near-term capital expenditure requirements?
Will the divestment of the Ewoyaa Project and focus on North American assets alter Elevra's geographic risk profile and exposure to regulatory changes in Canada versus Africa?


























